Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

NCT02891213 is registered in ClinicalTrials.gov with CHU de Reims as lead sponsor.

NCT NCT02891213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02891213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
Lead sponsor
CHU de Reims
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2016
Completion date
October 31, 2017
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lupus erythematosus